Tarsus to acquire Alkeus Pharma, adding retina repertoire

USA-based eye care specialist Tarsus Pharmaceuticals (Nasdaq: TARS) yesterday announced that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease.

The pending acquisition represents another important step in Tarsus' long-term strategy to build a leading eye care company by bringing differentiated medicines to patients with significant unmet needs, the company noted. It is expected to expand Tarsus’ growing presence in retina, complement the capabilities established through the acquisition of iRenix Medical, and add a differentiated Phase III program potentially addressing Stargardt disease. Tarsus’ shares gained 6.6% to $65.33 following the announcement.